TY - JOUR
T1 - The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner
AU - Agerbæk, Mette Ø
AU - Bang-Christensen, Sara R
AU - Yang, Ming-Hsin
AU - Clausen, Thomas M
AU - Pereira, Marina A
AU - Sharma, Shreya
AU - Ditlev, Sisse B
AU - Nielsen, Morten A
AU - Choudhary, Swati
AU - Gustavsson, Tobias
AU - Sorensen, Poul H
AU - Meyer, Tim
AU - Propper, David
AU - Shamash, Jonathan
AU - Theander, Thor G
AU - Aicher, Alexandra
AU - Daugaard, Mads
AU - Heeschen, Christopher
AU - Salanti, Ali
PY - 2018/8/16
Y1 - 2018/8/16
N2 - Isolation of metastatic circulating tumor cells (CTCs) from cancer patients is of high value for disease monitoring and molecular characterization. Despite the development of many new CTC isolation platforms in the last decade, their isolation and detection has remained a challenge due to the lack of specific and sensitive markers. In this feasibility study, we present a method for CTC isolation based on the specific binding of the malaria rVAR2 protein to oncofetal chondroitin sulfate (ofCS). We show that rVAR2 efficiently captures CTCs from hepatic, lung, pancreatic, and prostate carcinoma patients with minimal contamination of peripheral blood mononuclear cells. Expression of ofCS is present on epithelial and mesenchymal cancer cells and is equally preserved during epithelial-mesenchymal transition of cancer cells. In 25 stage I-IV prostate cancer patient samples, CTC enumeration significantly correlates with disease stage. Lastly, rVAR2 targets a larger and more diverse population of CTCs compared to anti-EpCAM strategies.
AB - Isolation of metastatic circulating tumor cells (CTCs) from cancer patients is of high value for disease monitoring and molecular characterization. Despite the development of many new CTC isolation platforms in the last decade, their isolation and detection has remained a challenge due to the lack of specific and sensitive markers. In this feasibility study, we present a method for CTC isolation based on the specific binding of the malaria rVAR2 protein to oncofetal chondroitin sulfate (ofCS). We show that rVAR2 efficiently captures CTCs from hepatic, lung, pancreatic, and prostate carcinoma patients with minimal contamination of peripheral blood mononuclear cells. Expression of ofCS is present on epithelial and mesenchymal cancer cells and is equally preserved during epithelial-mesenchymal transition of cancer cells. In 25 stage I-IV prostate cancer patient samples, CTC enumeration significantly correlates with disease stage. Lastly, rVAR2 targets a larger and more diverse population of CTCs compared to anti-EpCAM strategies.
KW - Adaptation, Physiological
KW - Antigens, Protozoan/metabolism
KW - Cell Line, Tumor
KW - Cell Separation
KW - Epithelial Cell Adhesion Molecule/metabolism
KW - Epithelial Cells/metabolism
KW - Epithelial-Mesenchymal Transition
KW - Humans
KW - Leukocytes, Mononuclear/metabolism
KW - Magnetics
KW - Male
KW - Mesoderm/metabolism
KW - Microspheres
KW - Neoplasm Staging
KW - Neoplastic Cells, Circulating/metabolism
KW - Pancreatic Neoplasms/blood
KW - Prostatic Neoplasms/metabolism
KW - Protein Binding
KW - Proto-Oncogene Proteins p21(ras)/genetics
KW - Recombinant Proteins/metabolism
UR - https://www.scopus.com/pages/publications/85051524776
U2 - 10.1038/s41467-018-05793-2
DO - 10.1038/s41467-018-05793-2
M3 - Journal article
C2 - 30115931
SN - 2041-1722
VL - 9
SP - 3279
JO - Nature Communications
JF - Nature Communications
IS - 1
ER -